Literature DB >> 33424848

COVID-19: Coronavirus Vaccine Development Updates.

Jing Zhao1, Shan Zhao1, Junxian Ou1, Jing Zhang2, Wendong Lan1, Wenyi Guan1, Xiaowei Wu1, Yuqian Yan1, Wei Zhao1, Jianguo Wu2, James Chodosh3, Qiwei Zhang1,2.   

Abstract

Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a newly emerged coronavirus, and has been pandemic since March 2020 and led to many fatalities. Vaccines represent the most efficient means to control and stop the pandemic of COVID-19. However, currently there is no effective COVID-19 vaccine approved to use worldwide except for two human adenovirus vector vaccines, three inactivated vaccines, and one peptide vaccine for early or limited use in China and Russia. Safe and effective vaccines against COVID-19 are in urgent need. Researchers around the world are developing 213 COVID-19 candidate vaccines, among which 44 are in human trials. In this review, we summarize and analyze vaccine progress against SARS-CoV, Middle-East respiratory syndrome Coronavirus (MERS-CoV), and SARS-CoV-2, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus like particles, nucleic acid vaccines, and viral vector vaccines. As SARS-CoV-2, SARS-CoV, and MERS-CoV share the common genus, Betacoronavirus, this review of the major research progress will provide a reference and new insights into the COVID-19 vaccine design and development.
Copyright © 2020 Zhao, Zhao, Ou, Zhang, Lan, Guan, Wu, Yan, Zhao, Wu, Chodosh and Zhang.

Entities:  

Keywords:  Coronavirus Disease 2019 (COVID-19); Middle-East Respiratory Syndrome; Severe Acute Respiratory Syndrome; Severe Acute Respiratory Syndrome Coronavirus 2; vaccine

Year:  2020        PMID: 33424848      PMCID: PMC7785583          DOI: 10.3389/fimmu.2020.602256

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  55 in total

1.  Detection and Prevention of Virus Infection.

Authors:  Ying Wang; Bairong Shen
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.

Authors:  Masaru Shimada; Haibin Wang; Motohide Ichino; Takehiro Ura; Nobuhisa Mizuki; Kenji Okuda
Journal:  Gene Ther       Date:  2022-01-06       Impact factor: 5.250

3.  Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP.

Authors:  Muzamil Jawed; Amna Khalid; Mayer Rubin; Ramsha Shafiq; Nail Cemalovic
Journal:  Open Forum Infect Dis       Date:  2021-06-24       Impact factor: 3.835

4.  Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure.

Authors:  Adrián Sánchez-Montalvá; Candela Fernández-Naval; Andrés Antón; Xavier Durà; Alba Vimes; Aroa Silgado; Fernando Velásquez-Orozco; Juan Espinosa-Pereiro; Fernando Salvador; Tomás Pumarola; Benito Almirante; Juliana Esperalba
Journal:  J Clin Med       Date:  2021-05-04       Impact factor: 4.241

5.  Production of SARS-CoV-2 Virus-Like Particles in Insect Cells.

Authors:  Youjun Mi; Tao Xie; Bingdong Zhu; Jiying Tan; Xuefeng Li; Yanping Luo; Fei Li; Hongxia Niu; Jiangyuan Han; Wei Lv; Juan Wang
Journal:  Vaccines (Basel)       Date:  2021-05-26

6.  The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2.

Authors:  Wael Alturaiki; Ayman Mubarak; Abduallah Al Jurayyan; Maged Gomaa Hemida
Journal:  Hum Vaccin Immunother       Date:  2021-06-11       Impact factor: 3.452

Review 7.  Pollution, Inflammation, and Vaccines: A Complex Crosstalk.

Authors:  Laura Franza; Rossella Cianci
Journal:  Int J Environ Res Public Health       Date:  2021-06-11       Impact factor: 3.390

Review 8.  COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern.

Authors:  Md Zeyaullah; Abdullah M AlShahrani; Khursheed Muzammil; Irfan Ahmad; Shane Alam; Wajihul Hasan Khan; Razi Ahmad
Journal:  Front Genet       Date:  2021-06-15       Impact factor: 4.599

9.  Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.

Authors:  Alina Renz; Lina Widerspick; Andreas Dräger
Journal:  Genes (Basel)       Date:  2021-05-24       Impact factor: 4.096

10.  An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.

Authors:  Ole A W Haabeth; Julian J K Lohmeyer; Adrienne Sallets; Timothy R Blake; Idit Sagiv-Barfi; Debra K Czerwinski; Blaine McCarthy; Abigail E Powell; Paul A Wender; Robert M Waymouth; Ronald Levy
Journal:  ACS Cent Sci       Date:  2021-06-18       Impact factor: 14.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.